Bioprocessing symposium to showcase biopharma and purification innovation
29 January 2026 | By
The three-day MSS2026 event takes place in September in Slovenia, with online attendance options also available.
List view / Grid view
29 January 2026 | By
The three-day MSS2026 event takes place in September in Slovenia, with online attendance options also available.
The pharma company’s injectable GLP-1/GIP receptor agonist CT-388 is an important element of its weight loss strategy and also delivered benefits for pre-diabetic patients.
Conclusion of ‘landmark’ deal significantly enhances trade, investment and supply chains, notably granting beneficial tariff reductions for the pharma industry.
Phase II data derived from the first randomised trial comparing immunotherapy outcomes post-FMT from immunotherapy responders versus placebo.
People, not platforms, will define the next era of innovation, explain Chiesi’s Executive VP of R&D Diego Ardigò and Nick Petschek, EMEA Managing Director at Kotter.
Disrupting drug-resistant Gram-negative pathogens is a potential breakthrough in addressing AMR and enhancing antibiotic success.
He brings 30 years of pharma industry experience to the role, principally in key manufacturing projects.
CGT Catapult research shows an increase in phase I/II trials, led by oncology but with clear growth in other disease areas such as inflammation.
The CRDMO will support the biotech company’s work on next-generation immunotherapies for oncology and autoimmune diseases.
Achieves 100 percent response in phase II data highlighting HT-001's potential as a supportive oncology treatment to address a common EGFR therapy burden.
New phase IIb data highlights the combination’s potential to offer improved efficiency to high-risk melanoma patients.
The East Coast expansion is part of the biopharma firm’s $50 billion investment in its US manufacturing and R&D capabilities.
EU Parliament agrees clear priorities for future negotiations on the act, including investing in pharma manufacturing capacity.
Will gain access to ozureprubart, a potential best-in-class antibody for food allergies, and expand its respiratory, immunology and inflammation pipeline.
Research findings support the design of robust microbial processes for pharmaceutical products.